Diana Șerban (Vitema) at Quarterly Report 3: “We have products at the highest quality standards”
April 1, 2024
Diana Șerban, Business Development Head at Vitema Pharmaceuticals, participated in the third edition of the Quarterly Report, the #1 event for companies on the BVB, branded by Ziare.com, together with main partner TradeVille, where she highlighted the company’s impressive plans, as well as the rebranding process it went through.
More specifically, Vitema Pharmaceuticals was until recently Polisano Pharmaceuticals, a company that has been operating for over 20 years in the pharmaceutical industry in Romania. Diana Șerban revealed the reasons behind the change, but also the direction for the year 2024. “Vitema is the name of a company that has more than 20 years of experience in the pharmaceutical industry in Romania, but the name probably doesn’t say anything to tonight’s audience so far. That’s because our company recently rebranded itself from Polisano to Vitema. This is a strategic decision of the new management team, which is led by the new CEO, Mr. Yassin Abdul, who took over the company in the second half of last year. This rebranding also represents a change in business strategy, from the production of our own portfolio of products, medicines and dietary supplements, to the contract manufacturing business, i.e. the production of medicines and supplements for third parties,”
Diana Serban said on stage at the Quarterly Report event.The rebranding came as a strategic decision both to make the most of the company’s assets and to align with market trends, Diana Șerban explained. “The rationale behind the rebranding is based on many reasons, but I will explain a little at a macro level. If we look at the last four years, we have seen a very accelerated dynamic in all industries and a repositioning of the strategy of companies to a greater or lesser extent, but especially those in the pharmaceutical industry. If you look at the big global companies, or Big Pharma, they have started to refocus their resources on their core business, which is the research, development and marketing of their own products, increasingly outsourcing production. If we look at the retailers in the pharmaceutical market, they have started to narrow down their product portfolio and focus more and more on selling their own brands, the production of which is also outsourced. And in this context, the strategic decision not only helps us to make the most of the company’s assets which are extremely valuable, but also to align with market trends,” said Diana Serban.
GMP Pharma Certification - the ace up Vitema's sleeve.
Vitema Pharmaceuticals differentiates itself from other contract manufacturing plants by GMP Pharma certification, among other things. It is a proof of superior quality, as the production process is subject to very strict rules when it comes to examination and verification.
“An extremely big advantage of our company is the GMP Pharma certification, which means that through the production we provide for both medicines and food supplements, they are produced to the highest quality standards, unlike other contract manufacturing factories, which either do not have this certification at all, which means they cannot guarantee the quality of the production process, or they have GMP for food supplements, which, although important, is not as rigorous as GMP Pharma, i.e. GMP for medicines. In other words, every supplement and every product that is produced in our factory goes through an extremely rigorous process of examination and quality control from the raw material to the finished product,” explained Diana Șerban.
Production capacity is also a strength of the company, and the figures presented by Diana Șerban are spectacular. “Another advantage of our company is the impressive production capacity, we are talking about an annual capacity of 3.5 billion capsules and tablets and 4,500 tons of powders and a 100% automated production process, which means that it allows us to have extremely low production costs, which are passed on to the customers, but it also allows us to execute each batch of medicine or supplement with speed and precision. I would also mention the team we have, which is one of our company’s most valuable assets. I would like to mention the research and development department, which is headed by Neil Carlsson, who is one of the best specialists in dietary supplement formulation in Europe,” Diana Șerban added.
Vitema Pharmaceuticals and DY Nutrition - a successful joint venture
Vitema Pharmaceuticals and DY Nutrition form a joint venture, as both Diana Șerban and Mircea Teacă, CEO of DY Nutrition, reported at the third edition of the Quarterly Report.
“Vitema and DY form a joint venture. Basically, our company gives DY the flexibility and agility to evolve its spectacular growth at an even faster pace, while at the same time offering the possibility to optimize formulations and expand the product range to new therapeutic areas,” said Diana Serban.
“For us, this joint venture with Vitema is a critical step in the company’s development. In order to ensure our forecasted growth, we need in-house production, thus securing production and the supply chain, which are quite difficult in this field”, said Mircea Teacă.
Post Related
Social Media
Download Our Brochure
Contact Our Team
Subscribe Now
Main Menu
Vitema
Manufacturing
Copyright © 2024 Vitema Pharmaceuticals
